Home/ Stocks/ BYSI

BeyondSpring Inc. Ordinary Shares

BYSI XNAS

$0.61 +0.02 (+3.42%) ▲ 15-min delayed

Open

$0.60

High

$0.65

Low

$0.60

Volume

40.3K

Market Cap

$24.78M

About BeyondSpring Inc. Ordinary Shares

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 44 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-5,700,000	$-0.02
Q1 2026	$0	$-6,674,000	$-0.05
FY 2025	$0	$-14,217,000	$-0.02
Q3 2025	$0	$-4,944,000	$-0.04

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 10, 2026

Calendar →

Related Market News

No specific coverage for BYSI yet. Check out our latest market news or earnings calendar.

Get BYSI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BeyondSpring Inc. Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.